vendredi 20 mai 2016

Onco Actu du 20 mai 2016


2.6 Etiologie - Environnement

EU delays vote on weed-killer glyphosate license amid cancer row [Reuters]

3. Prévention

Can Most Cancer Really Be Prevented? [TIME]

3.1 Tabac

Tobacco packs changed forever as the UK introduces plain packaging laws [Cancer Research UK]

Plain cigarette packaging has arrived, but will it reduce smoking? [The Guardian]

Tobacco firms lose high court battle over plain packaging [The Guardian]

3.8 Prévention - Alimentation

Why ‘healthy’ food is a bankrupt concept [STAT]

4.10 Dép., diag. & prono. - Poumon

Lung cancer breathalyzer in UK clinical trials [Reuters]

4.2 Dép., diag. & prono. - Génome

Myriad Announces Plans to Launch a Web Portal for Patients that Will Provide Access to Test Results, Tools and Health Information [Myriad]

4.8 Dép., diag. & prono. - Droit

Myriad Genetics' Statement on HIPAA Complaint from Four Patients [Myriad]

Patients challenge Myriad Genetics for access to their gene data [STAT]

After a prominent gene-testing firm declined to give patients their complete data, ACLU filed a legal complaint [Science]

Myriad hit with complaint over access to genetic information [Reuters]

5.10 Traitements - Essais

Better with bitcoin [The Economist]

5.12 Immunothérapies

Cancer can be combated with reprogrammed macrophage cells [Karolinska Institutet]

5.2 Pharma

Viehbacher, Germano--Epstein? Big Pharma execs, and the call of biotech [FierceBiotech]

Phase III study of Roche’s Alecensa (alectinib) showed superior efficacy versus crizotinib in Japanese people with a specific type of lung cancer [Roche]

5.2.3 Pharma - économie

The Real Reason Big Pharma Wants to Help Pay for Your Prescription [Bloomberg]

5.4 Traitements - Economie

ARIAD Announces Pricing and Reimbursement for Iclusig in France [ARIAD]

Vermont poised to become first state to require pharma to justify pricing [STAT]

Long term benefits of breast cancer drug pertuzumab too uncertain says NICE in draft guidance [NICE]

Breast cancer drug rejected despite doubling in tumour destruction [The Telegraph]

Roche breast cancer drug Perjeta rejected by UK cost agency [Reuters]

5.5.1 ASCO (général)

Moving Ahead In Cancer Care: 2016 ASCO Annual Meeting [The OBR Blog]

5.5.1.1 ASCO (général) - Industriels

8 Stocks on the Move After ASCO Cancer Abstracts [24/7 Wall St.]

Clovis Oncology Announces Data Presentations at 2016 ASCO Annual Meeting [Clovis]

5.5.4 ASCO (immunothérapies)

Merck's Keytruda shines in pre-ASCO abstract release, with Pfizer catching the limelight, too [FiercePharma]

5.5.7 ASCO (gynéco)

ImmunoGen Reports Efficacy and Safety Data from a 46-Patient Cohort of Mirvetuximab Soravtansine in FRα-Positive Ovarian Cancer [ImmunoGen]

6.1 Observation

Overweight Colorectal Cancer Patients Have Higher Survival Rate Than Normal-Weight Patients [Kaiser Permanente]

Global life expectancy increases to 71.4 years [The Guardian]

6.10 Politiques

New U.S. overtime rules will bump up postdoc pay, but could hurt research budgets [Science]

Postdoc pay to increase due to new overtime rule [Science]

US law could increase postdoc pay — and shake up research system [Nature News & Comment]

6.6 Publications

Retractions aren’t enough: Why science has bigger problems [Retraction Watch]